Same appointment mammogram results may result in less stress for patients being screened for breast cancer
1. Same appointment mammogram results had a positive impact on breast cancer screening experience...
Read More
Oncology
Pembrolizumab plus chemotherapy improved survival in a subgroup of triple-negative metastatic breast cancer
1. Pembrolizumab plus chemotherapy for triple-negative breast cancer significantly increased PFS...
Read More
Topical hypericin photodynamic therapy is effective and safe in early-stage T cell lymphoma
1. Hypericin photodynamic therapy was found to be more efficacious in treating early-stage T cell...
Read More
Survival is similar for patients with autoimmune disease treated with immune checkpoint inhibitors compared to patients with no autoimmune disease
1. There was no significant difference in efficacy of ICIs in cancer patients with or without AID....
Read More
Breast, colorectal, and cervical cancer screening was reduced during the COVID-19 pandemic as compared to pre-COVID time periods.
1. All cancer types had the greatest decrease in screening during the early part of the pandemic....
Read More
LCAR-B38M CAR-T cell therapy promising at 4-year follow-up for treatment of refractory multiple myeloma
1. At a 4-year follow-up for relapsed or refractory multiple myeloma (RRMM) patients treated with...
Read More
IsoPSA Shows Notable Diagnostic Accuracy in Detecting Prostate Cancer
The IsoPSA biomarker displays superior diagnostic accuracy in the early detection of prostate...
Read More
FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
1. Overall survival rate at 12 months for the FOLFOX arm and ipilimumab arm was 70% and 57%,...
Read More
Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
1. The pathologic response rate was similar in the atezolizumab treatment group as compared to...
Read More
Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
1. Median event-free survival in the liso-cel group was significantly greater than in the...
Read More
High tumour mutation burden in NSCLC associated with improved clinical outcomes of PD-L1 blockade across PD-L1 expression subgroups
1. High tumour mutation burden levels were associated with improvements in objective response...
Read More
Treatment of anal high-grade squamous intraepithelial lesions can reduce rates of progression to invasive anal cancer.
1. The rate of progression was 57% lower in the group receiving anal HSIL treatment as compared to...
Read More
Human papillomavirus (HPV) vaccination rates have increased in recent years
1. Between 2015 and 2020, human papillomavirus vaccination (HPV) rates in the United States...
Read More
Circulating Tumour DNA Analysis reduced adjuvant chemotherapy use while not compromising recurrence-free survival in stage II colon cancer
1. The circulating tumour DNA-guided approach was non-inferior to the standard clinicopathological...
Read More
Medical cannabis provides little improvement to sleep in chronic pain patients
1. In this systematic review and meta-analysis, medical cannabis and cannabinoids versus placebo...
Read More
No observed benefit of adjuvant everolimus combined with endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer
1. Disease-free survival did not differ significantly between patient groups and overall survival...
Read More
Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher...
Read More
Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
1. 5-year progression-free status was greatest in group 3 (triple therapy) and lowest in group 1...
Read More
Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer
1. Progression-free survival was longer for patients receiving tiragolumab with atezolizumab as...
Read More